Medline Inc. manufactures med-surg products serving the hospital, surgery centers, physician offices, post-acute facilities, and nursing home sites of care in the United States and Internationally. The company is headquartered in Northfield, Illinois.
| Revenue (TTM) | $30.68B |
| Gross Profit (TTM) | $7.49B |
| EBITDA | $2.70B |
| Operating Margin | 5.22% |
| Return on Equity | 4.84% |
| Return on Assets | 2.70% |
| Revenue/Share (TTM) | $34.90 |
| Book Value | $13.43 |
| Price-to-Book | 2.96 |
| Price-to-Sales (TTM) | 1.70 |
| EV/Revenue | 1.433 |
| EV/EBITDA | 16.21 |
| Quarterly Earnings Growth (YoY) | 1088.00% |
| Quarterly Revenue Growth (YoY) | 10.40% |
| Shares Outstanding | $878.66M |
| Float | $370.05M |
| % Insiders | 0.26% |
| % Institutions | 112.68% |
Volatility is currently expanding
Medline NASDAQ: MDLN reported third-quarter revenue growth of 10% year over year to $7.9 billion, supported by broad-based gains across its Medline Brand and Supply Chain Solutions businesses. Adjusted EBITDA increased 12% to $1 billion, while the company raised its full-year organic sales growth outlook for a third consecutive quarter.
While the top- and bottom-line numbers for Medline (MDLN) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
NORTHFIELD, Ill., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Medline Inc. (“Medline” or the “Company”) (Nasdaq: MDLN), the largest provider of medical-surgical (“med-surg”) products and supply chain solutions serving all points of care3, today reported its operating results for the three and nine months ended September 26, 2026.
NEW YORK, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Medline Inc. (NASDAQ:MDLN) for potential securities fraud after its significant stock drops. If you invested in Medline securities, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/medline-class-action-lawsuit.
NORTHFIELD, Ill., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Medline Inc. (“Medline”) (Nasdaq: MDLN) today announced that Jim Boyle, chief executive officer, is scheduled to present at the Jefferies Global Healthcare Conference in London on Tuesday, November 17, 2026, at 3:30pm Greenwich Mean Time (GMT).
NEW YORK, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Medline Inc. (NASDAQ:MDLN) for potential securities fraud after its significant stock drops. If you invested in Medline securities, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/medline-class-action-lawsuit.
NEW YORK, Oct. 29, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Medline Inc. ("Medline" or the "Company") (NASDAQ: MDLN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Medline Inc. (NASDAQ:MDLN) for potential securities fraud after its significant stock drops. If you invested in Medline securities, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/medline-class-action-lawsuit.
NEW YORK, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Medline Inc. (NASDAQ:MDLN) for potential securities fraud after its significant stock drops. If you invested in Medline securities, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/medline-class-action-lawsuit.
NEW YORK, Oct. 22, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Medline Inc. ("Medline" or the "Company") (NASDAQ: MDLN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on MDLN and any ticker you trade — then tracks every position and per-strategy win rate.
